News
Welcome to the news and media section of our website, where we feature corporate news releases and media coverage of interest.
Show by Tag
Settle® was one of the treatments assessed in a research abstract presented at the 2025 Bain Fallon Memorial Lectures in Australia and published in SciQuest. Settle improved pregnancy outcomes in BHS-positive mares.
Settle® immunotherapy for equine endometritis is now available in Canada. It's also sold in the USA, Australia, New Zealand and UAE. Settle is compatible with conventional treatments and is safe with natural breeding or AI.
NovaVive's immunotherapy for equine endometritis, Settle®, has received approval for sale in Canada from the Canadian Food Inspection Agency (CFIA). The product is expected to launch in the first quarter of this year.
Data from a U.S. study using NovaVive's immunotherapy for equine endometritis, Settle®, to treat endometrial cups was presented today at the International Symposium on Equine Reproduction (ISER) in Foz do Iguaçu, Brazil.
Data from a study conducted by Gluck Equine Research Center (UKY) and Rood & Riddle Equine Hospital has demonstrated efficacy of Settle® to treat endometrial cups in mares. No other treatment has been found effective to date.